CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning objectives:

- To place the results of correlative biological studies in the context of ongoing care of patients in Canada with malignant disease and to translate these results into clinical practice.
- To provide a learning environment supportive to new investigators, and to engage the academic pathology and research community in Canada in translational research initiatives associated with clinical trials.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to the diagnosis, prognosis, treatment, and adverse effects in the therapy of malignant disease.

8:00 Welcome and Introductions
8:10 Biomarkers of Immune-Oncology Therapies
8:15 Update of PD-L1 assays (M Tsao)
8:45 Immune Cell profiling as a biomarker (Marcus Butler)
9:00 Genome technologies to characterize cancer and immune systems in primary tissues (T Pugh)
9:30-10:00 Guidelines for pathologists involved in CCTG trials
- Consensus and Discussion (M Tsao)
10:00-10:30 CAPTUR (J Dancey)
CCSRI Review (L Shepherd/M Tsao)
COFFEE
CLOSED SESSION TO FOLLOW FOR SCIENTIFIC ADVISORY SUB COMMITTEE